Gilead Sciences (GILD)
Health Care · Biopharmaceuticals
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
What Gilead Sciences does
Gilead Sciences is a biopharmaceutical company that discovers, develops, and delivers innovative medicines to address life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide with a commercial portfolio of more than 25 approved therapies. Gilead focuses on advancing first-in-class therapies and enhanced treatment regimens with improved efficacy, resistance profiles, and safety profiles. The company generates substantial revenue from HIV products while expanding into oncology and liver disease treatments.
Themes: ["HIV treatment and prevention","Hepatitis C and B treatment","CAR-T cell therapy","Oncology (breast cancer, lymphomas)","Antiviral therapeutics","Cell therapy manufacturing"]
Fundamentals
- Price$134.84 as of 2026-07-09 close
- Market cap$166.0B as of 2026-07-10
- 1-year return+19.1% as of 2026-07-09 close
- P/E18.01 as of 2026-07-10
- Net margin+31.0% as of 2026-07-10
- Gross margin+79.3% as of 2026-07-10
- ROE+42.2% as of 2026-07-10
- Debt / equity0.94 as of 2026-07-10
- Revenue growth (YoY)+3.5% as of 2026-07-10
- Revenue CAGR (3y)+2.6% SEC XBRL
- Beta0.34 as of 2026-07-10
Dividend: yield +2.4%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["HIV revenue concentration: substantial portion of revenue comes from HIV products, vulnerable to generic competition and market share loss from competing antiretrovirals","Cell therapy manufacturing complexity: CAR-T manufacturing depends on third-party apheresis centers, logistics providers, and company-operated facilities; quality or supply disruptions could delay commercialization or regulatory action","Regulatory and reimbursement pressures: products subject to pricing controls, rebates, and reimbursement limitations from government and payers; CAR-T therapies face black box warnings for secondary malignancy risks and REMS requirements"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.